

## Case Control Study

# Intestinal parameters of oxidative imbalance in celiac adults with extraintestinal manifestations

Agnieszka Piatek-Guziewicz, Agata Ptak-Belowska, Magdalena Przybylska-Felus, Pawel Pasko, Pawel Zagrodzki, Tomasz Brzozowski, Tomasz Mach, Malgorzata Zwolinska-Wcislo

Agnieszka Piatek-Guziewicz, Department of Gastroenterology and Hepatology, University Hospital, Cracow 31531, Poland

Magdalena Przybylska-Felus, Tomasz Mach, Malgorzata Zwolinska-Wcislo, Department of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University Medical College, Cracow 31531, Poland

Agata Ptak-Belowska, Tomasz Brzozowski, Department of Physiology, Jagiellonian University Medical College, Cracow 31531, Poland

Pawel Pasko, Pawel Zagrodzki, Department of Food Chemistry and Nutrition, Jagiellonian University Medical College, Cracow 30688, Poland

Pawel Zagrodzki, Henryk Niewodniczanski Institute of Nuclear Physics, Cracow 31342, Poland

ORCID number: Agnieszka Piatek-Guziewicz (000 0-0002-7936-0249); Agata Ptak-Belowska (0000 -000 2-0294-5185); Magdalena Przybylska-Felus (000 0-000 2-8730-9670); Pawel Pasko (0000-0002-4821-4492); Pawel Zagrodzki (0000-0002-5101-036X); Tomasz Brzozowski (0000-0002-5805-0065); Tomasz Mach (0000-0002-4963-2354); Malgorzata Zwolinska-Wcislo (0000-0001-7868-1860).

**Author contributions:** Piatek-Guziewicz A, Zwolinska-Wcislo M and Ptak-Belowska A designed the research; Piatek-Guziewicz A, Ptak-Belowska A, Przybylska-Felus M, Pasko P and Zagrodzki P performed the research; Ptak-Belowska A analyzed the data; Piatek-Guziewicz A and Zwolinska-Wcislo M wrote the paper; Mach T and Brzozowski T revised and edited the manuscript for final submission.

**Supported by** Ministry of Science and Higher Education, No. K/ZDS/003811.

**Institutional review board statement:** The study was reviewed and approved by the Local Ethics Committee at Jagiellonian University Medical College in Cracow, Poland (No. KBET/174/B/2013).

**Informed consent statement:** All study participants, or their legal guardians, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors of this manuscript have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Tomasz Brzozowski, MD, PhD, Professor, Department of Physiology, Jagiellonian University Medical College, 16 Grzegorzeczka Street, Cracow 31-531, Poland. [mpbrzozo@cyf-kr.edu.pl](mailto:mpbrzozo@cyf-kr.edu.pl)  
Telephone: +48-12-4211006  
Fax: +48-12-4222014

**Received:** October 11, 2017

**Peer-review started:** October 11, 2017

**First decision:** October 18, 2017

**Revised:** November 3, 2017

**Accepted:** November 14, 2017

**Article in press:** November 14, 2017

**Published online:** November 28, 2017

## Abstract

### AIM

To evaluate selected intestinal parameters of oxidative stress, and antioxidant capacity in adult celiac disease patients with extraintestinal manifestations.

## METHODS

The study involved 85 adult patients divided into the following subgroups: (1) patients with newly diagnosed celiac disease (CD) ( $n = 7$ ); (2) celiac patients not adhering to a gluten-free diet (GFD) ( $n = 22$ ); (3) patients with CD on the GFD ( $n = 31$ ); and (4) patients with functional disorders of the gastrointestinal tract, serving as controls ( $n = 25$ ). Celiac patients presented with non-classic symptoms or extraintestinal manifestations. Standard blood tests including serum antioxidant levels (uric acid, bilirubin, and vitamin D), celiac antibody levels, and histopathological status of duodenal biopsy specimens have been determined. The expression of mRNA for tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin 1 $\beta$  (IL-1 $\beta$ ), interleukin 10 (IL-10), superoxide dismutase (SOD), heat-shock protein 70 (HSP-70), hypoxia-inducible factor 1 (HIF-1 $\alpha$ ), and BAX in the duodenal mucosa of patients was analyzed by reverse transcriptase-polymerase chain reaction.

## RESULTS

The mean plasma uric acid level in patients with active CD (newly diagnosed and nonadherent patients) and treated celiac patients was significantly higher than in controls ( $260.17 \pm 53.65$  vs  $190.8 \pm 22.98$ ,  $P < 0.001$ , and  $261.7 \pm 51.79$  vs  $190.8 \pm 22.98$ ,  $P < 0.001$ , respectively). The mean bilirubin concentration in active and treated celiac patients was significantly lower than in controls ( $8.23 \pm 5.04$  vs  $10.48 \pm 4.08$ ,  $P < 0.05$  and  $8.06 \pm 3.31$  vs  $10.48 \pm 4.08$ ,  $P < 0.05$ , respectively). The mean plasma vitamin D level was significantly lower in active celiac patients than in treated celiac patients and controls ( $19.37 \pm 9.03$  vs  $25.15 \pm 11.2$ ,  $P < 0.05$  and  $19.37 \pm 9.03$  vs  $29.67 \pm 5.12$ ,  $P < 0.001$ , respectively). The expression of TNF- $\alpha$ , IL-10, and HSP-70 mRNAs was significantly elevated in the celiac groups regardless of the diet when compared with controls. Patients on the GFD presented a significantly lower mRNA expression of TNF- $\alpha$  and IL-10 than in newly diagnosed and nonadherent patients ( $P < 0.05$ ). The expression of SOD mRNA was significantly elevated in celiac patients compared with controls ( $P < 0.05$ ), with a significant difference between treated and untreated patients ( $P < 0.05$ ). The expression of HIF-1 $\alpha$  mRNA and BAX mRNA was significantly higher in patients with active CD compared with controls and patients on GFD, while no difference was observed between the latter two groups.

## CONCLUSION

Increased intestinal expression of HSP-70 despite GFD indicates that GFD only partially reduced oxidative stress. CD patients exhibited an oxidative imbalance and inflammatory response despite GFD. Uric acid may act as an important antioxidant in CD.

**Key words:** Celiac disease; Oxidative stress; Superoxide dismutase; Heat-shock protein 70; Apoptosis; Hypoxia-inducible factor; Uric acid; Vitamin D; Tumor necrosis factor alpha

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Oxidative stress has been implicated in gliadin toxicity. Additional measures aimed at reducing oxidative imbalance may prove to be effective supplementary therapy. We demonstrated increased duodenal expression of hypoxia-inducible factor 1 (HIF-1 $\alpha$ ), heat-shock protein 70 (HSP-70), and superoxide dismutase in adult celiac patients with extraintestinal manifestations as a defensive reaction to oxidative stress. Hence, HSP-70 and HIF-1 $\alpha$  might be potential novel biomarkers of celiac disease (CD). Increased HSP-70 expression, both in treated and untreated celiac patients, suggests that oxidative stress as well as histopathological alterations in duodenal mucosa persist despite gluten-free diet. Our data confirm the increased serum levels of uric acid in patients with CD compared with controls as a result of oxidative stress.

Piatek-Guziewicz A, Ptak-Belowska A, Przybylska-Felus M, Pasko P, Zagrodzki P, Brzozowski T, Mach T, Zwolinska-Weislo M. Intestinal parameters of oxidative imbalance in celiac adults with extraintestinal manifestations. *World J Gastroenterol* 2017; 23(44): 7849-7862 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i44/7849.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i44.7849>

## INTRODUCTION

Celiac disease (CD) is an inflammatory disorder of the small intestine, which is caused by the gluten fraction of wheat or the homologous proteins from barley and rye in genetically predisposed individuals<sup>[1]</sup>. Histologically, these lesions include intraepithelial lymphocytosis, crypt hypertrophy, and villous atrophy, resulting in an inadequate absorption of micronutrients and macronutrients from the intestinal tract. The clinical presentation of CD is heterogeneous and varies with the age of patients, duration and intensity of the disease, and possible presence of extraintestinal disorders<sup>[1]</sup>. In adults, a variety of clinical manifestations have been described, including the non-classic or asymptomatic form of CD.

The pathogenesis of CD is complex and not fully understood. Besides genetic predisposition, the immunologic mechanism has been proposed because both the innate and adaptive immune responses contribute to the mucosal inflammation in patients with CD<sup>[2]</sup>. The disruption of the intestinal epithelial barrier makes it more permeable to gluten peptides, thus exacerbating the inflammatory process if gluten peptides are present in the intestinal lumen.

Recent studies have indicated a direct cytotoxic effect of gluten on enterocytes<sup>[3]</sup>. Moreover, it has been proposed that oxidative stress is one of the

mechanisms responsible for gliadin toxicity<sup>[4]</sup>. Recent data have also suggested the importance of hypoxia-inducible factor 1 (HIF-1) in maintaining the functions of the intestinal epithelial barrier<sup>[5]</sup>. Although activation of HIF-1 is mainly regulated by hypoxia<sup>[6]</sup>, it is now established that HIF-1 signaling can also be triggered under inflammatory conditions<sup>[7-10]</sup>. Vannay *et al.*<sup>[11]</sup> have shown the increased mucosal expression of HIF-1 $\alpha$  in children with untreated CD, suggesting the involvement of this signaling factor in the pathomechanism of the disease. The regulation of HIF-1 is a complex process. Among these regulatory mechanisms, a direct effect of reactive oxygen species (ROS) on the HIF-1 $\alpha$  subunit has received a great deal of attention, but there are contradictory literature data with respect to association between HIF-1 $\alpha$  and ROS<sup>[12]</sup>. Some studies have indicated that heat shock proteins and the family of chaperones could play important roles in the pathology of CD<sup>[13-15]</sup>. The expression of HSPs can be markedly upregulated in epithelial cells under extreme conditions by the mechanism involving the expression and release of proinflammatory mediators, such as tumor necrosis factor alpha (TNF- $\alpha$ ) or an activation of oxidative stress<sup>[16]</sup>. All these factors can trigger apoptosis<sup>[17,18]</sup>, but the decision for a cell to undergo apoptosis depends on the balance between proapoptotic and antiapoptotic signals. For instance, HSPs may exert antiapoptotic effects and contribute to preservation of intestinal epithelial barrier integrity<sup>[19]</sup>. This process can be executed either by the extrinsic or intrinsic apoptotic pathways. While the role of the extrinsic apoptotic pathway activation in the mucosa of patients with CD has been proposed in the literature, studies on the intrinsic and common apoptotic pathways in patients with CD are sparse<sup>[18]</sup>.

It is likely that the development of CD depends on the balance between proinflammatory and anti-inflammatory factors, proapoptotic and antiapoptotic signals, as well as prooxidant processes and antioxidant capacity of the cell. This imbalance is reflected in an impairment of the epithelial barrier and increased permeability, leading to activation of the immune response (native and adaptive) that contributes to cell damage and villous atrophy in patients with CD.

The aim of our study was to determine the involvement of oxidative imbalance in the mechanism of mucosal injury of the small intestine and to assess the effect of oxidative stress on the course of CD in adult patients with non-classic symptoms and extraintestinal manifestations. Apart from routine blood parameters, the serum concentrations of total vitamin D, uric acid, and bilirubin were measured. Moreover, in biopsy specimens collected during endoscopy of the proximal small intestine from these groups of patients, the expression of mRNA for proinflammatory cytokines TNF- $\alpha$  and interleukin 1 $\beta$  (IL-1 $\beta$ ) as well as an anti-

inflammatory cytokine interleukin 10 (IL-10) was determined by reverse transcription-polymerase chain reaction (RT-PCR) with specific primers. Oxidative stress may influence the expression of HSP-70, another marker examined in our study. Since ROS were shown to affect the stabilization of HIF-1 $\alpha$  RNA and activate the intrinsic apoptotic pathway associated with overexpression of proapoptotic BAX, we also examined the gene expression of HIF-1 $\alpha$ , antioxidant enzyme SOD, and proapoptotic factor BAX in the duodenal tissues of the enrolled patients.

## MATERIALS AND METHODS

All individuals gave informed consent to participate in the study. The protocol of the study was approved by the Ethical Committee at Jagiellonian University Medical College in Cracow, Poland (No KBET/174/B/2013) and was run in accordance with the Declaration of Helsinki.

The study included 85 patients of the Outpatient Clinic and the Department of Gastroenterology and Hepatology of the University Hospital in Cracow (Table 1). Patients were divided into the following subgroups: (1) 7 patients with newly diagnosed CD (age range, 19-62 years; mean age, 34.7  $\pm$  14.9 years); (2) 22 patients with CD who did not adhere to GFD (nontreated CD group; age range, 22-68 years; mean age, 38.2  $\pm$  10.7 years); (3) 31 patients with CD who were on GFD for at least two years and who tested negative for celiac antibodies (treated CD group; age range, 28-65 years; mean age, 45.7  $\pm$  16.1 years; mean duration, 10  $\pm$  7.7 years); and (4) 25 patients with functional disorders of the gastrointestinal tract without abnormalities on upper gastrointestinal endoscopy and on serological and histological examinations (control group; age range 19-66 years; mean age, 38.5  $\pm$  13.2 years). Groups 1 and 2 represented patients with active CD.

CD was diagnosed on the basis of clinical symptoms, positive test results for celiac antibodies [antitissue transglutaminase antibodies (TGAs) or antiendomysial antibodies (EmAs) or both], and the characteristic histological features of duodenal biopsies. Celiac patients presented with non-classic symptoms or extraintestinal manifestations such as iron deficiency, anemia, chronic abdominal pain without typical malabsorption syndrome, osteoporosis, osteopenia, as well as asymptomatic disease (Table 2). We excluded patients with diabetes, inflammatory bowel disease, current infectious disease, history of cancer, chronic hepatobiliary disease, chronic renal impairment, and alcohol abuse, or those who received therapy with nonsteroidal anti-inflammatory drugs, antioxidant supplements, oral contraceptives, immunosuppressants, and immunostimulants. All patients were nonsmokers.

All patients underwent upper gastrointestinal endoscopy, and at least four well-oriented duodenal

specimens were taken for histological examination and determination of the IL-1 $\beta$ , TNF- $\alpha$ , IL-10, HSP-70, HIF-1 $\alpha$ , SOD, and BAX mRNA expression in the duodenum. The degree of intestinal mucosal damage was evaluated according to the Marsh classification<sup>[20]</sup>. The histological assessment was performed by an experienced pathologist in the Department of Pathology at Jagiellonian University Medical College.

We determined the serum levels of TGAs and EmAs, blood cell count, serum activity of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,  $\gamma$ -glutamyltransferase, and total protein, as well as serum levels of antioxidants: uric acid, bilirubin, and vitamin D. The TGA concentration was assessed using a commercial ELISA kit (Aesku Diagnostics GmbH, Germany), and the results were expressed as unit (U)/mL of serum. A value higher than 15 U/mL was considered positive. EmAs were assessed with immunofluorescence. A value higher than 1:10 was considered positive. The other biochemical tests were performed in the Department of Diagnostics of the University Hospital in Cracow.

#### **Expression of IL-1 $\beta$ , TNF- $\alpha$ , IL-10, HSP-70, HIF-1 $\alpha$ , SOD, and BAX transcripts in the human intestinal samples determined by RT-PCR**

The expression of IL-1 $\beta$ , TNF- $\alpha$ , IL-10, HSP-70, HIF-1 $\alpha$ , SOD, and BAX transcripts in human samples was determined by RT-PCR. Each specimen was immediately frozen in liquid nitrogen and stored at -80 °C until analysis. Total RNA was then isolated according to the method by Chomczynski and Sacchi<sup>[21]</sup>, using Trizol Reagent (Invitrogen, Carlsbad, United States) following the manufacturer's protocol. First-strand cDNA was synthesized from total cellular RNA (2  $\mu$ g) using Reverse Transcription System (Promega, Madison, United States). The RT-PCR was carried out in an automatic DNA thermal cycler, using 1- $\mu$ g cDNA and Promega PCR reagents. For amplification of IL-1 $\beta$ , TNF- $\alpha$ , IL-10, HSP-70, HIF-1 $\alpha$ , SOD, and BAX cDNA, gene-specific primers were used (SIGMA-Aldrich St. Louis, United States) (Table 3). Amplification of control human  $\beta$ -actin was performed on the same samples to verify the RNA integrity. PCR products were separated by electrophoresis in 2% agarose gel containing 0.5  $\mu$ g/mL of ethidium bromide and then visualized under ultraviolet light. Location of the predicted PCR product was confirmed by using the O'Gene Ruler 50 bp DNA ladder (Fermentas, Life Sciences, San Francisco, United States) as standard marker.

#### **Statistical analysis**

A statistical analysis was performed by a biomedical statistician using a nonparametric Mann-Whitney test. For the comparison of normally distributed variables

between the groups, the Student's *t*-test was used. The results were reported as mean  $\pm$  SE or mean  $\pm$  SD, and a significance level was defined as a *P* value of less than 0.05. The analysis was performed using Statistica 10 software (StatSoft® Inc., United States).

## **RESULTS**

### **Blood test in controls and celiac patients**


The results of biochemical tests are presented in Table 4. The mean leukocyte and platelet counts were similar between the celiac groups and controls. The mean red blood cell count was lower in the active CD and treated CD groups as compared with controls ( $4.49 \pm 0.39$  vs  $4.7 \pm 0.37$ ,  $P < 0.05$ ;  $4.45 \pm 0.42$  vs  $4.7 \pm 0.37$ ,  $P < 0.05$ , respectively). The mean hemoglobin and hematocrit levels were lower in patients with active CD than in controls ( $12.6 \pm 1.8$  vs  $13.4 \pm 1.4$ ,  $P < 0.05$ ;  $37.6 \pm 4.4$  vs  $41.6 \pm 9.6$ ,  $P < 0.05$ , respectively) and treated celiac patients ( $12.6 \pm 1.8$  vs  $13.3 \pm 1.1$ ,  $P < 0.05$ ;  $37.6 \pm 4.4$  vs  $39.5 \pm 3.2$ ,  $P < 0.05$ , respectively). Only 2 patients (3.3%) with CD were anemic (hemoglobin  $< 11$  g/dL), but reduced mean corpuscular volume was observed in 11 patients (37.9%) with active CD (range, 59.9–81.4 fL), in 3 patients (3.2%) with treated CD (range, 80.9–81.1 fL), and in two controls (8%; range, 80.1–80.4 fL).

The mean serum levels of total protein, alanine aminotransferase, alkaline phosphatase, and  $\gamma$ -glutamyltransferase were similar to those observed in controls. The mean serum levels of aspartate aminotransferase were significantly higher in the active CD and treated CD groups compared with controls ( $28.0 \pm 19.3$  vs  $18.0 \pm 8.5$ ,  $P < 0.05$ ;  $23.2 \pm 6.5$  vs  $18.0 \pm 8.5$ ,  $P < 0.05$ , respectively), without significant differences between the two CD groups. Hypertransaminasemia was reported in 7 patients (24.1%) with active CD, in 5 patients (16.1%) with treated CD, and in none of the control patients.

Serum uric acid concentrations were elevated only in celiac patients, namely, in 3 patients (10.3%) with active CD and in 2 patients (6.5%) on GFD. Uric acid levels were significantly higher in the celiac groups than in controls ( $P < 0.001$ ), while bilirubin levels were significantly lower in patients with CD than in controls ( $P < 0.05$ ).

Reduced vitamin D levels were reported in 26 patients (89.6%) with active CD, in 21 patients (67.7%) with treated CD, and in 14 controls (56%). Moderate vitamin D deficiency (10–19 ng/mL) was reported in 11 patients (37.9%) with active CD and 12 patients ( $< 10$  ng/mL) was reported in 3 patients (10.3%) with active CD and only in 1 patient (3.2%) with treated CD. Moderate to severe vitamin D deficiency was not observed in the control group. The mean vitamin D





**Figure 1** The spectrum of small intestinal damage in the study groups. Hematoxylin and eosin stained biopsy specimens obtained by gastroscopy. A: Normal duodenal mucosa: normal villus-to-crypt ratio; intraepithelial lymphocytes (IEL) within the normal range; B: Marsh 1: lymphocytic enteritis (an increase in IEL count); C: Marsh 3a: partial villous atrophy with hypertrophic crypts and an increase in IEL count; D: Marsh 3b: subtotal villous atrophy with hypertrophic crypts and an increase in IEL count; E: Marsh 3c: total villous atrophy with hypertrophic crypts and an increase in IEL count.

**Table 1** Characteristics of the study groups

Groups of patients	Age (yr, mean $\pm$ SD)	n (%)
Total	70.74 $\pm$ 14.22	85
Female		71 (83.5)
Male		14 (16.5)
Active CD		
Newly diagnosed CD	34.7 $\pm$ 14.9	7
Female		5 (71.4)
Male		2 (28.6)
Nontreated CD	38.2 $\pm$ 10.7	22
Female		18 (81.8)
Male		4 (18.2)
Treated CD	45.7 $\pm$ 16.1	31
Female		28 (90.3)
Male		3 (9.7)
Control	38.5 $\pm$ 13.2	25
Female		20 (80)
Male		5 (20)

Active CD: Celiac patients with active disease; Newly diagnosed CD: Celiac patients at diagnosis of CD; Nontreated CD: Celiac patients not adhering to a gluten-free diet; Treated CD: Celiac patients on a gluten-free diet.

level was significantly lower in patients with active CD than in controls or treated celiac patients ( $P < 0.001$  and  $P < 0.05$ , respectively), and was lower in treated


celiac patients than in controls ( $P < 0.05$ ).

#### **Serum levels of celiac antibodies and the degree of intestinal mucosal damage in the study population**

The serum levels of celiac antibodies were negative in the control group (Table 5). As expected, the significantly higher levels of celiac antibodies were observed in patients with active CD. In treated CD patients, the levels of antibodies were significantly lower compared with untreated CD patients ( $P < 0.001$ ). The degree of intestinal mucosal damage evaluated according to the Marsh classification as shown in Figure 1 and Table 5 was the most severe in newly diagnosed CD patients, followed by nontreated CD patients, treated CD patients, and controls. The differences between the groups were significant. Data are presented in Table 5.

#### **Expression of transcripts in human intestinal samples determined by reverse-transcriptase polymerase chain reaction**

**Expression of IL-1 $\beta$ , TNF- $\alpha$ , and IL-10:** Figure 2 shows the mRNA expression of proinflammatory cytokines IL-1 $\beta$  and TNF- $\alpha$  and the alterations in RT-PCR mRNA expression of anti-inflammatory cytokine



**Figure 2** The RT-PCR expression of mRNA for  $\beta$ -actin (A), interleukin 1 $\beta$  (B), tumor necrosis factor  $\alpha$  (C), and interleukin 10 (D) in duodenal tissue of celiac patients and controls. The bands densities [as a ratio of interleukin-1 $\beta$  (IL-1 $\beta$ ), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and IL-10 to the  $\beta$ -actin levels, respectively] are expressed as the mean  $\pm$  SE of 4 determinations in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCCD: Newly diagnosed celiac group. <sup>a</sup> $P < 0.05$  vs control group; <sup>c</sup> $P < 0.05$  vs control and treated CD groups.

**Table 2** Clinical characteristic of study groups  $n$  (%)

Groups of patients	Iron deficiency/anemia	Chronic abdominal pain	Osteopenia/osteoporosis	Menstrual disorders	Abnormal liver tests	Others
Active CD ( $n = 29$ )	11 (37.9)	7 (24.1)	4 (13.8)	1 (3.4)	5 (17.2)	1 (3.4)
Treated CD ( $n = 31$ )	15 (48.4)	4 (12.9)	5 (16.1)	-	5 (16.1)	2 (6.5)


Active CD: Celiac patients with active disease; Treated CD: Celiac patients on a gluten-free diet.

IL-10 in the biopsies of duodenal mucosa. The IL-1 $\beta$  mRNA expression was not significantly different between the study groups, although it was slightly higher in active CD as compared with controls and patients on GFD. The expression of mRNA for TNF- $\alpha$  was significantly increased in all celiac groups when compared with controls ( $P < 0.05$ ). The TNF- $\alpha$  RNA expression was similar in both groups of active CD (high degree of mucosal damage), but was significantly higher than in treated patients (low grade of mucosal damage).

The expression of IL-10 mRNA in the study groups was similar to the trend observed for the expression

of TNF- $\alpha$  mRNA. In intact intestinal mucosa, the signal for IL-10 mRNA expression was faint. However, we observed a significant increase in the IL-10 mRNA expression in the celiac groups when compared with controls ( $P < 0.05$ ). Celiac patients on GFD had a lower expression of IL-10 mRNA in the mucosa than patients with active disease, and this difference based on the semi-quantitative assessment of the ratio of IL-10 mRNA expression to  $\beta$ -actin mRNA expression was significant (Figure 2).

**Expression of HSP-70 and SOD:** As shown in Figure 3, the signal for the expression of HSP-70 mRNA was



**Figure 3** The RT-PCR expression of mRNA for  $\beta$ -actin (A), heat-shock protein 70 (B) and superoxide dismutase (C) in duodenal tissue of celiac patients and controls. The band densities [as a ratio of heat-shock protein 70 (HSP-70) and superoxide dismutase (SOD) to the  $\beta$ -actin levels, respectively] are expressed as the mean  $\pm$  SE of 4 determinations in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCD: Newly diagnosed celiac group. <sup>a</sup> $P < 0.05$  vs control group; <sup>c</sup> $P < 0.05$  vs control and treated CD groups.

**Table 3** Human oligonucleotide primers for detection of mRNA by RT-PCR

Gene	Primer sequence	<i>t</i>	PCR product
IL-1 $\beta$	Forward 5'-ACA TCA GCA CCT CTC AAG -3', Reverse 5'-AGT CCA CAT TCA GCA CAG -3'	60 °C	141 bp
TNF- $\alpha$	Forward 5'-GCC CAG GCA GTC AGA TCA TCT TC -3', Reverse 5'-TGA GGT ACA GGC CCT CTG ATG G-3'	58 °C	181 bp
IL-10	Forward 5'-AGC TAT CCC AGA GCC CCA GAT CCG ATT TTG G-3', Reverse 5'-AAG CTG AGA ACC AAG ACC CAG ACA TCA AGG CG-3'	60 °C	328 bp
HSP-70	Forward: 5'-GCC CCA ACA GAT TGT TGT CTT-3', Reverse: 5'-CCA CCA AGC AGA CGC AGA T-3'	59.5 °C	111 bp
HIF-1 $\alpha$	Forward 5'-GGT TCT CAC AGA TGA TGG TG-3', Reverse 5'-TTC TTC CTC GGC TAG TTA GG-3'	60 °C	239 bp
SOD	Forward: 5'-GAA GGT GGG AAG CAT TA-3', Reverse: 5'-ACC TTT GCC CAA GTC ATC TG-3'	57 °C	300 bp
BAX	Forward 5'-CGT CCA ACC CAC CCT GGT CT-3', Reverse 5'-TGG CAG CTG ACA TGT TTT CTG AC-3'	55 °C	195 bp
$\beta$ -actin	Forward 5'-GGG TAC ATG GTG GTG CCG-3', Reverse 5'-AGC GGG AAA TCG TGC GTG-3'	54 °C	307 bp

*t*: Annealing temperature; IL-1 $\beta$ : Interleukin 1 $\beta$ ; TNF- $\alpha$ : Tumor necrosis factor  $\alpha$ ; IL-10: Interleukin 10; HSP-70: Heat-shock protein 70; HIF-1 $\alpha$ : Hypoxia-inducible factor 1 $\alpha$ ; SOD: Superoxide dismutase.


markedly increased in the celiac groups compared with controls, regardless of compliance with the diet ( $P < 0.05$ ). The differences between the celiac groups were not significant.

The ratio of SOD mRNA expression to  $\beta$ -actin mRNA expression confirmed that the expression of this antioxidant enzyme was significantly elevated in celiac patients compared with controls ( $P < 0.05$ ). The signal for SOD mRNA expression in treated CD patients was significantly lower than in untreated and newly diagnosed ones (Figure 3).

**Expression of HIF-1 $\alpha$  and BAX:** The ratio of HIF-

1 $\alpha$  mRNA expression to  $\beta$ -actin mRNA expression confirmed that the expression of HIF-1 $\alpha$  was significantly elevated in the mucosa of patients with active CD compared with controls and patients with treated CD ( $P < 0.05$ ). HIF-1 $\alpha$  mRNA expression was slightly increased in the duodenal mucosa of patients with treated CD compared with controls, but the difference was not significant (Figure 4). A significant increase in the expression of BAX mRNA as determined by the ratio of BAX mRNA expression to  $\beta$ -actin mRNA expression in the mucosa of patients with active CD was observed compared with controls and patients





**Figure 4** The RT-PCR expression of mRNA for  $\beta$ -actin (A), hypoxia-inducible factor 1 $\alpha$  (B) and BAX (C) in duodenal tissue of celiac patients and controls. The band densities [as a ratio of hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) and BAX to the  $\beta$ -actin levels, respectively] are expressed as the mean  $\pm$  SE of 4 determinations in selected patients. TCD: Treated celiac group; NTCD: Nontreated celiac group; NDCD: Newly diagnosed celiac group. <sup>a</sup> $P < 0.05$  vs control and treated CD groups.

**Table 4** Blood test results in the study groups

	Controls (n = 25)	Active CD (n = 29)	Treated CD (n = 31)
WBC ( $10^3/\mu\text{L}$ )	5.69 $\pm$ 1.55	5.81 $\pm$ 1.58	5.36 $\pm$ 1.36
RBC ( $10^6$ cells/ $\mu\text{L}$ )	4.7 $\pm$ 0.37	4.49 $\pm$ 0.39 <sup>a</sup>	4.45 $\pm$ 0.42 <sup>a</sup>
Hemoglobin (g/dL)	13.4 $\pm$ 1.4	12.6 $\pm$ 1.8 <sup>a,c</sup>	13.3 $\pm$ 1.1
Hematocrit (%)	41.6 $\pm$ 9.6	37.6 $\pm$ 4.4 <sup>a,c</sup>	39.5 $\pm$ 3.2
PLT ( $10^3/\mu\text{L}$ )	248.52 $\pm$ 47.63	267.18 $\pm$ 96.8	252.52 $\pm$ 64.38
Vitamin D (ng/mL)	29.7 $\pm$ 5.1	19.4 $\pm$ 9.0 <sup>b,c</sup>	25.2 $\pm$ 11.2 <sup>a</sup>
Total protein (g/L)	73.2 $\pm$ 6.1	71.2 $\pm$ 7.9	71.6 $\pm$ 3.3
AST (U/L)	18.0 $\pm$ 8.5	28.0 $\pm$ 19.3 <sup>a</sup>	23.2 $\pm$ 6.5 <sup>a</sup>
ALT (U/L)	22.0 $\pm$ 4.3	26.7 $\pm$ 20.1	24.2 $\pm$ 12.5
AP (U/L)	59.6 $\pm$ 19.7	62.2 $\pm$ 29.1	59.2 $\pm$ 27.3
GGTP (U/L)	24.4 $\pm$ 14.6	21.3 $\pm$ 13.6	21.3 $\pm$ 22.62
bilirubin ( $\mu\text{mol/L}$ )	10.5 $\pm$ 4.1	8.2 $\pm$ 5.0 <sup>a</sup>	8.1 $\pm$ 3.3 <sup>a</sup>
Uric acid ( $\mu\text{mol/L}$ )	190.8 $\pm$ 23.0	260.2 $\pm$ 53.7 <sup>b</sup>	261.7 $\pm$ 51.8 <sup>b</sup>

Data are given as mean  $\pm$  SD. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.001$  vs controls; <sup>c</sup> $P < 0.05$  vs Treated CD. Active CD: Patients with active CD; Treated CD: Celiac patients on a gluten-free diet; WBC: White blood cell count; RBC: Red blood cell count; PLT: Platelet count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AP: Alkaline phosphatase; GGTP:  $\gamma$ -glutamyltransferase.

with treated CD ( $P < 0.05$ ). We failed to observe any significant difference in the expression of BAX mRNA in the duodenal mucosa of patients with treated CD compared with controls (Figure 4).

## DISCUSSION

Most studies concerning the pathomechanism of CD and intestinal changes focused on children with classic clinical symptoms of malabsorption syndrome<sup>[4,22-24]</sup>.

However, malabsorption alone does not explain the pathophysiology and clinical course of numerous extraintestinal manifestations as well as non-classic symptoms that predominate in adult patients with CD. Other mechanisms have been proposed including gluten toxicity with oxidative imbalance and autoimmunity<sup>[23,24]</sup>.

In this study, we have examined less extensively studied, factors implicated in CD, such as HSP-70, HIF-1 $\alpha$ , and the proapoptotic factor BAX. We found these 3 factors to be overexpressed in active CD, with varying degrees of activity in patients on GFD. This overexpression could be triggered by oxidative imbalance linked with an increase in ROS generation. Each of these factors was shown to influence the intestinal barrier integrity. For instance, HSP-70 and HIF-1 $\alpha$  can contribute to preservation of intestinal barrier integrity<sup>[5,19]</sup>, while apoptosis manifested by the rise in the BAX expression may lead to disruption of the intestinal barrier<sup>[25]</sup>. The impaired barrier function may be involved in several immune-mediated diseases, including CD and its extraintestinal manifestations or coexisting disorders<sup>[26,27]</sup>.

HSP, a known chaperone, has potential epithelial barrier protecting, antiapoptotic, and immunologic properties<sup>[19]</sup>, but its role in the pathogenesis of CD remains unexplored. Our results presented in this work revealed that HSP-70, which is expressed under normal conditions, can also play a particularly important role in extreme conditions such as gluten cytotoxicity. It is noteworthy that the expression of HSP-70 was significantly increased in each celiac group in our study



**Table 5** Clinical characteristics of the study groups: serum levels of celiac antibodies and the degree of intestinal mucosal damage *n* (%)

	Control ( <i>n</i> = 25)	Treated CD ( <i>n</i> = 31)	Nontreated CD ( <i>n</i> = 22)	Newly diagnosed CD ( <i>n</i> = 7)
Antibody titer				
0	25	30 (96.7)	0	0
1	0	1 (3.3)	9 (40.9)	1 (14.3)
2	0	0	3 (13.6)	2 (28.6)
3	0	0	10 (45.5)	4 (57.1)
Antibody titer	0	0.03 ± 0.2	2.0 ± 0.9 <sup>b,d</sup>	2.4 ± 0.8 <sup>b,d</sup>
Degree of intestinal mucosal damage <sup>1</sup>				
Normal mucosa 0	24 (96)	13 (41.3)	2 (9)	1 (14.3)
Marsh 1 1	1 (4)	5 (16.1)	7 (31.8)	0
Marsh 2 2	0	0	0	0
Marsh 3a 3	0	5 (16.1)	6 (27.3)	1 (14.3)
Marsh 3b 4	0	7 (22.6)	5 (22.7)	3 (42.9)
Marsh 3c 5	0	1 (3.2)	2 (9)	2 (28.6)
Intestinal mucosal damage <sup>1</sup>	0.04 ± 0.2	1.7 ± 1.8 <sup>b</sup>	2.5 ± 1.6 <sup>b,c</sup>	3.7 ± 1.4 <sup>b,c</sup>

<sup>1</sup>Intestinal mucosal damage was classified according to Marsh parameters, and each stage was given a score from 0 (normal mucosa) to 5 (total villous atrophy). <sup>b</sup>*P* < 0.001 *vs* controls; <sup>c</sup>*P* < 0.05, <sup>d</sup>*P* < 0.001 *vs* treated CD. Data are frequency counts (percentage of total) or the mean ± SD. Treated CD: Celiac patients on a gluten-free diet; Nontreated CD: Celiac patients not adhering to a gluten-free diet; Newly diagnosed CD: Celiac patients at diagnosis of CD; antibody titer 0: Negative; 1: Low [TGA <3x the upper limit of normal (ULN); EmA (+)]; 2: High [3xULN < TGA <10x ULN; EmA (++)]; 3: Very high [TGA >10x ULN; EmA (+++)].

regardless of the degree of compliance with the diet. A few previous studies evaluated the role of HSP in intestinal pathology of patients with CD<sup>[19,28-30]</sup>. Ilanen *et al.*<sup>[31]</sup> reported enhanced expression of epithelial cell mitochondrial HSP-65 in 80% of study children with CD and in only 7% of control subjects. Sziksz *et al.*<sup>[19]</sup> reported an increased HSP-72 mRNA expression in the duodenal mucosa of children with untreated CD as well as children with treated CD compared with that in controls. These observations are consistent with the results of our study on HSP-70 expression in adult patients. Our results indicate that HSP-70 in adult CD patients, similarly as HSP-72 in children, was overexpressed due to oxidative stress. The increased HSP-70 expression may constitute a protective mechanism against gliadin-induced cytotoxicity associated with antiapoptotic effects, thus contributing to preservation of intestinal epithelial barrier integrity.

It should be noted, however, that significant percentage of patients with CD on GFD, in our study, showed the persistence of duodenal damage despite clinical improvement and evident decline in celiac antibodies. The main criteria for inclusion in this group involved a specialist assessment by gastroenterologist and dietitian of patients proper dietary adherence, clinical recovery and above all, the negativity of serologic markers. Interestingly, a gap has emerged between the clinical and mucosal recovery, mainly in the adult population, since when re-biopsing treated CD patients only half of them had healed mucosa, despite the negativity of celiac antibodies<sup>[32,33]</sup>. Following the GFD, the clinical symptoms and mucosal architecture usually improve very quickly in children<sup>[34]</sup>, while in a mixed population including adults, the recovery of duodenal mucosa assessed by histology requires longer time to heal<sup>[35]</sup>. These previous observations seem consistent with the results of our

present study because the morphological alterations persisted in some of our CD patients despite the clear disappearance of specific antibodies. The increased expression of HSP-70 in treated and untreated celiac patients indicates that oxidative stress in patients with CD may still persist despite GFD and serological and clinical remission, and may be responsible for histopathological alterations observed in our study. Finally, the enhanced expression of HSP-70 suggest incomplete elimination of all sources of gluten in modern diet. Perhaps the expression of HSP-70 could be considered as a more sensitive marker than celiac antibodies in the detection of the trace amounts of gluten in diet. Thus, HSP-70 could be considered a potential novel biomarker of this disease.

It is known that ROS and HIF-1 signaling are involved in numerous diseases including cancer, inflammatory diseases, and ischemic disorders<sup>[12]</sup>. Furthermore, the increase of ROS levels is one of the main factors stabilizing HIF-1α. It has been shown that exogenous ROS, in the form of H<sub>2</sub>O<sub>2</sub>, can enhance the synthesis of inflammatory mediators such as TNF-α and IL-1β<sup>[36]</sup>, which in turn can influence the protein transcription and activity of HIF-1α under normoxia<sup>[37]</sup>. We provided evidence for the increased mucosal HIF-1α expression in untreated adult patients with active CD compared with controls and treated CD patients, while we did not observe any significant difference between treated celiac patients and controls. This observation is consistent with that of Vannay *et al.*<sup>[11]</sup>, who suggested the role of HIF-1α in the pathomechanism of CD. In addition, involvement of HIF-1 in inflammatory bowel disease has been reported<sup>[10]</sup>. The increased expression of HIF-1α in our study can be explained by the initial intestinal damage or the direct effect of gluten in diet. These data suggest that increased HIF-1α expression may

be a consequence rather than a primary cause of CD. Moreover, the decreased mucosal expression of HIF-1 $\alpha$  in treated CD may confirm the efficacy of GFD.

In general, data on the status of apoptosis in patients with CD are conflicting, but increased apoptotic cell death of intestinal epithelial cells was reported in untreated CD, as detected by DNA fragmentation assay using terminal uridine deoxynucleotidyl nick end labelling in small intestinal biopsies<sup>[38]</sup>. In that study, apoptosis was well correlated with proliferation and returned to normal in patients treated with GFD<sup>[38]</sup>. It is likely that increased apoptosis may be responsible for villous atrophy in CD. Therefore, our study included RT-PCR analysis of the proapoptotic member of the Bcl-2 family, that is, BAX, which in normal mucosa showed constitutive expression. This remains in keeping with the observation that the mucosa of healthy individuals undergoes a high rate of constitutive epithelial proliferation<sup>[17]</sup>. In our study, the expression of BAX showed a similar trend to that observed for the expression of HIF-1 $\alpha$ . We revealed a significantly elevated BAX mRNA expression in the duodenal mucosa of patients with active CD compared with controls and patients with treated CD. Interestingly, the expression of BAX mRNA in the duodenal mucosa was not significantly different between treated CD patients and controls. Our results suggest that the increased expression of BAX results from the severity of intestinal inflammation and gluten-induced oxidative stress and leads to duodenal villous atrophy. Moreover, the decreased mucosal expression of BAX in treated CD patients may indicate the relief of inflammation and thus the efficacy of treatment. In contrast to our study, van der Woude *et al.*<sup>[38]</sup> failed to demonstrate any changes in the expression of BAX, Bcl-2, and Bcl-xl between their study groups, which were similar to those in our study. However, Chervinsky *et al.*<sup>[39]</sup> found that only Bak mRNA was significantly overexpressed in the mucosa of CD patients, whereas BAX and Bcl-2 transcription levels were unchanged with respect to control mucosa.

Oxidative imbalance seems to be involved in the molecular mechanisms of CD. In normal conditions, the harmful effects of ROS are opposed by the antioxidant defense system consisting of antioxidant enzymes (glutathione peroxidase, glutathione reductase, SOD, and catalase), non-enzymatic antioxidants (such as glutathione, albumin, bilirubin, ceruloplasmin, and uric acid) as well as nutritional antioxidants (carotenoids and vitamins A, C, and E)<sup>[40]</sup>. The reduced antioxidant defense may make the inflamed mucosa more sensitive to oxidative tissue damage and may disrupt its recovery and integrity.

Using thiobarbituric acid reactive substances as a marker of oxidative stress, Odetti *et al.*<sup>[41]</sup> showed that redox equilibrium is impaired in patients with CD. They also observed decreased serum  $\alpha$ -tocopherol levels

in patients with silent CD in comparison with controls. Earlier studies also showed that the activity of SOD is markedly increased in pediatric patients with CD, while the activity of glutathione peroxidase is significantly decreased<sup>[24]</sup>.

SOD, which reduces the most abundant free radical  $\cdot\text{O}_2$ , is considered as the major intracellular antioxidant enzyme<sup>[40]</sup>. In agreement with previous data, our results demonstrated overexpression of SOD mRNA in the mucosa of celiac patients compared with controls. We observed an increased expression of SOD mRNA in active disease, and this increase was attenuated in the treated celiac group. These results suggest that the increased expression of SOD, reflecting the severity of oxidative stress in duodenal mucosa, could be a consequence of either intestinal impairment or of oxidative imbalance. Our observations may indicate that some markers of oxidative stress persist even in treated CD patients, but GFD partially counteracts the impairment of intestinal mucosa observed in active CD patients.

There is increasing experimental and clinical evidence showing that uric acid acts as an important antioxidant *in vivo*<sup>[42]</sup>. Interestingly, an increase in serum uric acid concentrations occurs as a physiological response to enhanced oxidative stress<sup>[43]</sup>. Despite being a major antioxidant in the human plasma, uric acid correlates with and may predict the development of conditions associated with oxidative stress such as obesity, hypertension, and cardiovascular disease<sup>[44]</sup>. Our results indicate that higher serum levels of uric acid in patients with CD compared with controls may be a consequence of oxidative stress and that uric acid may function as an antioxidant. Additional well-designed clinical studies are needed to clarify the potential use of uric acid (or uric acid precursors) in CD and to examine its role as a marker of oxidative stress and a potential therapeutic antioxidant.

In contrast to transaminases, the levels of bilirubin in patients with CD were significantly lower than in the control group. Bilirubin is an antioxidant that blocks vascular cell adhesion molecule 1 signals through ROS *in vitro*<sup>[45]</sup>. An Australian study<sup>[46]</sup> reported that bilirubin levels were significantly lower in severe asthma, suggesting altered regulation of inflammation in asthmatics by antioxidant vitamins and bilirubin. This observation is consistent with our results, indicating the relationship between the altered concentration of bilirubin and oxidative imbalance. However, the role of bilirubin in oxidative imbalance in CD requires further research.

A significant number of CD patients with intestinal malabsorption syndrome present vitamin D deficiency or insufficiency. In our study, vitamin D deficiency was noted in celiac patients despite the absence of clinical syndrome of malabsorption, possibly because inflammation may also lead to vitamin D deficiency.

It is likely that inflammatory cytokines, such as TNF- $\alpha$ , cause CYP27B1-mediated conversion of 25(OH)D to 1,25(OH) $_2$ D in the intestines, thereby reducing serum 25(OH) D levels<sup>[47]</sup>. In turn, the active form of 1,25(OH) $_2$ D inhibits the proliferation and secretion of inflammatory cytokines by type 1 helper T cells, thereby reducing inflammation<sup>[48]</sup>. This inverse relationship between the activity of CD and serum vitamin D levels was observed in our study. A similar observation concerns the degree of TNF- $\alpha$  expression and the degree of vitamin D deficiency, which is consistent with the results obtained in previous studies in healthy individuals<sup>[49,50]</sup>. The antioxidant property of vitamin D is rather less well recognized. Cholecalciferol (vitamin D $_3$ ) is likely to act as a membrane antioxidant by stabilizing the membrane against lipid peroxidation<sup>[51]</sup>. The antioxidant activity of vitamin D may involve an interaction with SOD<sup>[52]</sup>. We showed that a decrease in serum vitamin D levels in patients with CD was accompanied by an increase in the intestinal mucosal expression of TNF- $\alpha$ , suggesting that overexpressed TNF- $\alpha$  may lead to a reduction in the serum level of vitamin D. In turn, an increase in SOD expression may result from enhancement of TNF- $\alpha$  expression and a prominent fall in serum vitamin D levels which activate the antioxidative defense. This indicates that early diagnosis of vitamin D deficiency is particularly important in patients with CD, especially in those who do not comply with GFD. Therefore, the supplementation of vitamin D is recommended not only for bone metabolism but also for effective treatment of intestinal damage in patients with CD by reducing the oxidative stress.

A drawback of this study is a relatively small number of patients in each celiac subgroups, and definitely a further research with higher number of enrolled subjects is required to support our observations. It is noteworthy that the morphology of duodenal mucosa failed to show a full recovery despite the proper adherence to GFD, clinical improvement and the status of seroconversion, *i.e.* the decline in the value of antibodies in this group of patients to a negative result. Hence, further research with only subjects presenting full mucosal healing would add more to our understanding of pathomechanism of CD and intestinal recovery associated with GFD.

In conclusion, by its association with intestinal damage, the course of the disease, and perhaps extraintestinal disorders, oxidative imbalance appears to be one of the major factors implicated in the pathogenesis of CD. Our results support the hypothesis that HSP-70 may be a potential novel biomarker in CD. The increased intestinal expression of HSP-70 in patients with active CD and in treated celiac patients indicates that oxidative stress persists despite the exclusion of gluten from diet which deepens our knowledge on multifaceted mechanisms of this disease. This persistent oxidative imbalance may be responsible for sustained intestinal damage in CD despite GFD. In

fact, the significant overexpression of HSP-70 despite dietary compliance may suggest refractory nature of CD. Furthermore, particularly noteworthy are non-enzymatic antioxidants, such as uric acid and bilirubin, whose concentration may be easily assessed in patients with CD.

Considering that several nutrients exert antioxidant effects and influence gene expression, they represent a useful approach for nutritional intervention in CD subjects, as confirmed by recent studies *in vitro*. These studies have revealed phytonutrients and docosahexaenoic acid efficacy in protection against the cytotoxic effect of gliadin<sup>[53-55]</sup>.

To become aware of the usefulness of nutritional genomics as a tool for targeted medical nutrition therapy, further basic research, epidemiological studies and controlled intervention trials are needed to investigate whether some nutrients such as antioxidant vitamins modulate *in vivo* predisposition of chronic inflammatory conditions and thus, have a role in the therapy of celiac disease, in addition to the rigorous GFD.

## ARTICLE HIGHLIGHTS

### Research background

Celiac disease (CD) is a common condition. The only effective treatment available is a strict life-long gluten-free diet (GFD). Untreated CD can have serious complications, such as osteoporosis or malignancy. Some patients do not report symptomatic improvement after starting treatment, and some will still have persisting symptoms after 6 to 12 mo. The literature suggests that complete normalization of duodenal lesions is exceptionally rare in adult celiac patients despite adherence to GFD.

### Research motivation

There is an increasing body of evidence suggesting a relationship between oxidative stress and CD. It has been proposed that oxidative stress is one of the mechanisms responsible for gliadin toxicity and persistent oxidative imbalance may be responsible for sustained intestinal damage in CD despite GFD.

### Research objectives

The assessment of the severity of oxidative stress, including the evaluation of antioxidant capacity, in patients with CD may have therapeutic implications. The indication of a proper new biomarkers useful in assessing the individual susceptibility to oxidative stress, which may help elucidate the pathogenesis of the disease and implement an appropriate treatment.

### Research methods

To determine the involvement of oxidative stress in the mechanism of mucosal injury of the small intestine and to assess the effect of oxidative stress on the course of CD in adult patients with non-classic symptoms and extraintestinal manifestations, we determined the expression of IL-1 $\beta$ , TNF- $\alpha$ , IL-10, HSP-70, HIF-1 $\alpha$ , SOD and BAX transcripts in human duodenal samples by reverse transcriptase-polymerase chain reaction.

### Research results

The authors found HSP-70, HIF-1 $\alpha$ , and BAX to be overexpressed in active CD, with varying degrees of activity in patients on GFD. This overexpression could be triggered by oxidative imbalance linked with an increase in ROS generation. We observed an increased expression of SOD mRNA in active disease, and this increase was attenuated in the treated celiac group. These results suggest that the increased expression of SOD, reflecting the severity of oxidative stress

in duodenal mucosa, could be a consequence of either intestinal impairment or of oxidative imbalance.

Our results indicate that oxidative stress persists even in CD patients treated with GFD. Moreover, the results suggest that HSP-70 and HIF-1 $\alpha$  may be potential novel biomarkers of this disease. The overexpression of HSP-70 despite dietary compliance may suggest refractory nature of CD. The increased levels of uric acid in patients with CD compared with controls resulting from oxidative stress indicates that uric acid may function as an antioxidant compound.

Further research with a greater number of participants is needed to confirm our results. Further clinical studies are needed to clarify the potential therapeutic role of uric acid as an antioxidant in CD.

## Research conclusions

This study deepens the current knowledge on the role of oxidation products on the CD. By its association with intestinal damage, the course of the disease, and perhaps extraintestinal disorders, oxidative imbalance appears to be one of the major factors implicated in the pathogenesis of CD. Our observations may indicate that some markers of oxidative stress persist even in treated CD patients, but GFD partially counteracts the impairment of intestinal mucosa observed in active CD patients. Persistent oxidative imbalance may be responsible for sustained intestinal damage in adult celiac patients despite GFD. Perhaps the expression of HSP-70 could be considered as a more sensitive marker than celiac antibodies in the detection of the trace amounts of gluten in diet. Thus, HSP-70 could be considered a potential novel biomarker of this disease. Additional well-designed clinical studies are needed to clarify the potential use of uric acid (or uric acid precursors) in the diagnosis and prognosis of CD and to examine its role as a marker of oxidative stress and a potential therapeutic utility as an antioxidant. Considering that oxidative stress is involved in the molecular mechanisms of CD, additional measures aimed at reducing oxidative imbalance, such as administration of antioxidants, deserve attention as potential supplementary therapy in the treatment of CD, in addition to the rigorous GFD.

## Research perspectives

Studies comparing the different assays for antioxidant capacity measurement in patients with CD are needed to select the method of choice that would best reflect susceptibility to oxidative stress in these patients. These assays might be particularly useful in clinical practice as a tool for therapy monitoring in patients with CD. It should be hypothesized that oral antioxidant supplementation may reduce the toxic effects of peptides contained in gluten on enterocytes and help alleviate histological lesions, thus exerting beneficial effects on the course of the disease. To become aware of the usefulness of nutritional genomics as a tool for targeted medical nutrition therapy, further basic research, epidemiological studies and controlled intervention trials are needed to investigate whether some nutrients such as antioxidant vitamins modulate *in vivo* predisposition of chronic inflammatory conditions and thus have a role in the therapy of celiac disease, in addition to the rigorous GFD.

## REFERENCES

- Esteve M, Rosinach M, Fernández-Bañares F, Farré C, Salas A, Alsina M, Vilar P, Abad-Lacruz A, Forné M, Mariné M, Santaolalla R, Espinós JC, Viver JM. Spectrum of gluten-sensitive enteropathy in first-degree relatives of patients with coeliac disease: clinical relevance of lymphocytic enteritis. *Gut* 2006; **55**: 1739-1745 [PMID: 16709658 DOI: 10.1136/gut.2006.095299]
- Stepniak D, Koning F. Celiac disease--sandwiched between innate and adaptive immunity. *Hum Immunol* 2006; **67**: 460-468 [PMID: 16728270 DOI: 10.1016/j.humimm.2006.03.011]
- Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. *Nutrition* 1996; **12**: 274-277 [PMID: 8862535 DOI: 10.1016/S0899-9007(96)00000-8]
- Ferretti G, Bacchetti T, Masciangelo S, Saturni L. Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. *Nutrients* 2012; **4**: 243-257 [PMID: 22606367 DOI: 10.3390/nu4040243]
- Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. *J Clin Invest* 2004; **114**: 1098-1106 [PMID: 15489957 DOI: 10.1172/JCI200421086]
- Weidemann A, Johnson RS. Biology of HIF-1 $\alpha$ . *Cell Death Differ* 2008; **15**: 621-627 [PMID: 18259201 DOI: 10.1038/cdd.2008.12]
- Hirota SA, Beck PL, MacDonald JA. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. *Recent Pat Inflamm Allergy Drug Discov* 2009; **3**: 1-16 [PMID: 19149741]
- Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. *Trends Biochem Sci* 2008; **33**: 526-534 [PMID: 18809331 DOI: 10.1016/j.tibs.2008.08.002]
- Dehne N, Brüne B. HIF-1 in the inflammatory microenvironment. *Exp Cell Res* 2009; **315**: 1791-1797 [PMID: 19332053 DOI: 10.1016/j.yexcr.2009.03.019]
- Kapoor A, Patwari AK, Kumar P, Jain A, Narayan S. Serum soluble interleukin-2 receptor, interleukin-6 and tumor necrosis factor alpha as markers of celiac disease activity. *Indian J Pediatr* 2013; **80**: 108-113 [PMID: 22766904 DOI: 10.1007/s12098-012-0830-9]
- Vannay A, Sziksz E, Prókai A, Veres G, Molnár K, Szakál DN, Onódy A, Korponay-Szabó IR, Szabó A, Tulassay T, Arató A, Szebeni B. Increased expression of hypoxia-inducible factor 1 $\alpha$  in coeliac disease. *Pediatr Res* 2010; **68**: 118-122 [PMID: 20453713 DOI: 10.1203/00006450-201011001-00227]
- Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1 $\alpha$  by reactive oxygen species: new developments in an old debate. *J Cell Biochem* 2015; **116**: 696-703 [PMID: 25546605 DOI: 10.1002/jcb.25074]
- Zamanian Azodi M, Peyvandi H, Rostami-Nejad M, Safaei A, Rostami K, Vafaei R, Heidari M, Hosseini M, Zali MR. Protein-protein interaction network of celiac disease. *Gastroenterol Hepatol Bed Bench* 2016; **9**: 268-277 [PMID: 27895852]
- Tukaj S, Görög A, Kleszczynski K, Zillikens D, Kárpáti S, Kasperkiewicz M. Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformis. *J Steroid Biochem Mol Biol* 2017; **173**: 23-27 [PMID: 27760369 DOI: 10.1016/j.jsbmb.2016.10.002]
- Setty M, Discepolo V, Abadie V, Kamhawi S, Mayassi T, Kent A, Ciszewski C, Maglio M, Kistner E, Bhagat G, Semrad C, Kupfer SS, Green PH, Guandalini S, Troncone R, Murray JA, Turner JR, Jabri B. Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac Disease. *Gastroenterology* 2015; **149**: 681-91. e10 [PMID: 26001928 DOI: 10.1053/j.gastro.2015.05.013]
- van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. *Nat Rev Immunol* 2005; **5**: 318-330 [PMID: 15803151 DOI: 10.1038/nri1593]
- Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. *J Cell Sci* 1994; **107** ( Pt 12): 3569-3577 [PMID: 7706406]
- Shalimar DM, Das P, Sreenivas V, Gupta SD, Panda SK, Makharia GK. Mechanism of villous atrophy in celiac disease: role of apoptosis and epithelial regeneration. *Arch Pathol Lab Med* 2013; **137**: 1262-1269 [PMID: 23991739 DOI: 10.5858/arpa.2012-0354-OA]
- Sziksz E, Veres G, Vannay A, Prókai A, Gál K, Onódy A, Korponay-Szabó IR, Reusz G, Szabó A, Tulassay T, Arató A, Szebeni B. Increased heat shock protein 72 expression in celiac disease. *J Pediatr Gastroenterol Nutr* 2010; **51**: 573-578 [PMID: 20818265 DOI: 10.1097/MPG.0b013e3181ea0092]
- Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. *Eur J Gastroenterol Hepatol* 1999; **11**: 1185-1194 [PMID: 10524652 DOI: 10.1097/00042737-199910000-00019]
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987; **162**: 156-159 [PMID: 2440339 DOI: 10.1016/0003-2697(87)90021-2]



- 22 **Stojiljković V**, Todorović A, Radlović N, Pejić S, Mladenović M, Kasapović J, Pajović SB. Antioxidant enzymes, glutathione and lipid peroxidation in peripheral blood of children affected by coeliac disease. *Ann Clin Biochem* 2007; **44**: 537-543 [PMID: 17961308 DOI: 10.1258/000456307782268075]
- 23 **Stojiljković V**, Todorović A, Pejić S, Kasapović J, Saicić ZS, Radlović N, Pajović SB. Antioxidant status and lipid peroxidation in small intestinal mucosa of children with celiac disease. *Clin Biochem* 2009; **42**: 1431-1437 [PMID: 19560448 DOI: 10.1016/j.clinbiochem.2009.06.009]
- 24 **Stojiljković V**, Pejić S, Kasapović J, Gavrilović L, Stojiljković S, Nikolić D, Pajović SB. Glutathione redox cycle in small intestinal mucosa and peripheral blood of pediatric celiac disease patients. *An Acad Bras Cienc* 2012; **84**: 175-184 [PMID: 22441607]
- 25 **Youle RJ**, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. *Nat Rev Mol Cell Biol* 2008; **9**: 47-59 [PMID: 18097445 DOI: 10.1038/nrm2308]
- 26 **Liu Z**, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. *Acta Paediatr* 2005; **94**: 386-393 [PMID: 16092447 DOI: 10.1111/j.1651-2227.2005.tb01904.x]
- 27 **Monsuur AJ**, Wijmenga C. Understanding the molecular basis of celiac disease: what genetic studies reveal. *Ann Med* 2006; **38**: 578-591 [PMID: 17438672 DOI: 10.1080/07853890600989054]
- 28 **Partanen J**, Milner C, Campbell RD, Mäki M, Lipsanen V, Koskimies S. HLA-linked heat-shock protein 70 (HSP70-2) gene polymorphism and celiac disease. *Tissue Antigens* 1993; **41**: 15-19 [PMID: 8096093]
- 29 **Ramos-Arroyo MA**, Feijóo E, Sánchez-Valverde F, Aranburu E, Irisarri N, Olivera JE, Valiente A. Heat-shock protein 70-1 and HLA class II gene polymorphisms associated with celiac disease susceptibility in Navarra (Spain). *Hum Immunol* 2001; **62**: 821-825 [PMID: 11476906 DOI: 10.1016/S0198-8859(01)00277-4]
- 30 **Zanoni G**, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, Beri R, Dolcino M, Valletta E, Corrocher R, Puccetti A. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. *PLoS Med* 2006; **3**: e358 [PMID: 16984219 DOI: 10.1371/journal.pmed.0030358]
- 31 **Iltanen S**, Rantala I, Laippala P, Holm K, Partanen J, Maki M. Expression of HSP-65 in jejunal epithelial cells in patients clinically suspected of coeliac disease. *Autoimmunity* 1999; **31**: 125-132 [PMID: 10680751 DOI: 10.3109/08916939908994056]
- 32 **Lanzini A**, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, Turini D, Carella G, Malagoli A, Ferrante G, Cesana BM, Ricci C. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. *Aliment Pharmacol Ther* 2009; **29**: 1299-1308 [PMID: 19302264 DOI: 10.1111/j.1365-2036.2009.03992.x]
- 33 **Lebwohl B**, Granath F, Ekblom A, Smedby KE, Murray JA, Neugut AI, Green PH, Ludvigsson JF. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. *Ann Intern Med* 2013; **159**: 169-175 [PMID: 23922062 DOI: 10.7326/0003-4819-159-3-201308060-00006]
- 34 **McNicholl B**, Egan-Mitchell B, Stevens F, Keane R, Baker S, McCarthy CF, Fottrell PF. Mucosal recovery in treated childhood celiac disease (gluten-sensitive enteropathy). *J Pediatr* 1976; **89**: 418-424 [PMID: 956966 DOI: 10.1016/S0022-3476(76)80539-2]
- 35 **Wahab PJ**, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. *Am J Clin Pathol* 2002; **118**: 459-463 [PMID: 12219789 DOI: 10.1039/EVXT-851X-WHLC-RLX9]
- 36 **Haddad JJ**, Olver RE, Land SC. Antioxidant/pro-oxidant equilibrium regulates HIF-1 $\alpha$  and NF-kappa B redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. *J Biol Chem* 2000; **275**: 21130-21139 [PMID: 10801793 DOI: 10.1074/jbc.M000737200]
- 37 **Westra J**, Brouwer E, Bos R, Posthumus MD, Doornbos-van der Meer B, Kallenberg CG, Limburg PC. Regulation of cytokine-induced HIF-1 $\alpha$  expression in rheumatoid synovial fibroblasts. *Ann N Y Acad Sci* 2007; **1108**: 340-348 [PMID: 17893997 DOI: 10.1196/annals.1422.035]
- 38 **Moss SF**, Attia L, Scholes JV, Walters JR, Holt PR. Increased small intestinal apoptosis in coeliac disease. *Gut* 1996; **39**: 811-817 [PMID: 9038662 DOI: 10.1136/gut.39.6.811]
- 39 **Cherňavský AC**, Rubio AE, Vanzulli S, Rubinstein N, de Rosa S, Fainboim L. Evidences of the involvement of Bak, a member of the Bcl-2 family of proteins, in active coeliac disease. *Autoimmunity* 2002; **35**: 29-37 [PMID: 11908704 DOI: 10.1080/08916930290005945]
- 40 **Krinsky NI**. Mechanism of action of biological antioxidants. *Proc Soc Exp Biol Med* 1992; **200**: 248-254 [PMID: 1579590 DOI: 10.3181/00379727-200-43429]
- 41 **Odetti P**, Valentini S, Aragno I, Garibaldi S, Pronzato MA, Rolandi E, Barreca T. Oxidative stress in subjects affected by celiac disease. *Free Radic Res* 1998; **29**: 17-24 [PMID: 9733018 DOI: 10.1080/10715769800300031]
- 42 **Glantzounis GK**, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. *Curr Pharm Des* 2005; **11**: 4145-4151 [PMID: 16375736 DOI: 10.2174/138161205774913255]
- 43 **Waring WS**, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. *J Cardiovasc Pharmacol* 2001; **38**: 365-371 [PMID: 11486241 DOI: 10.1097/00005344-200109000-00005]
- 44 **Sautin YY**, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. *Nucleosides Nucleotides Nucleic Acids* 2008; **27**: 608-619 [PMID: 18600514 DOI: 10.1080/15257770802138558]
- 45 **Cook-Mills JM**, McCary CA. Isoforms of vitamin E differentially regulate inflammation. *Endocr Metab Immune Disord Drug Targets* 2010; **10**: 348-366 [PMID: 20923401 DOI: 10.2174/1871530311006040348]
- 46 **Misso NL**, Brooks-Wildhaber J, Ray S, Vally H, Thompson PJ. Plasma concentrations of dietary and nondietary antioxidants are low in severe asthma. *Eur Respir J* 2005; **26**: 257-264 [PMID: 16055873 DOI: 10.1183/09031936.05.00006705]
- 47 **Schoen MS**, Lindenbaum J, Roginsky MS, Holt PR. Significance of serum level of 25-hydroxycholecalciferol in gastrointestinal disease. *Am J Dig Dis* 1978; **23**: 137-142 [PMID: 623077 DOI: 10.1007/BF01073189]
- 48 **Ooi JH**, McDaniel KL, Weaver V, Cantorna MT. Murine CD8 $^{+}$  T cells but not macrophages express the vitamin D 1 $\alpha$ -hydroxylase. *J Nutr Biochem* 2014; **25**: 58-65 [PMID: 24314866 DOI: 10.1016/j.jnutbio.2013.09.003]
- 49 **Peterson CA**, Heffernan ME. Serum tumor necrosis factor- $\alpha$  concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm (Lond)* 2008; **5**: 10 [PMID: 18652680 DOI: 10.1186/1476-9255-5-10]
- 50 **Willis KS**, Smith DT, Broughton KS, Larson-Meyer DE. Vitamin D status and biomarkers of inflammation in runners. *Open Access J Sports Med* 2012; **3**: 35-42 [PMID: 24198585 DOI: 10.2147/OAJSM.S31022]
- 51 **Wiseman H**. Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. *FEBS Lett* 1993; **326**: 285-288 [PMID: 8325381 DOI: 10.1016/0014-5793(93)81809-E]
- 52 **Margulies SL**, Kurian D, Elliott MS, Han Z. Vitamin D deficiency in patients with intestinal malabsorption syndromes--think in and outside the gut. *J Dig Dis* 2015; **16**: 617-633 [PMID: 26316334 DOI: 10.1111/1751-2980.12283]
- 53 **Bernardo D**, Martínez-Abad B, Vallejo-Diez S, Montalvillo E, Benito V, Anta B, Fernández-Salazar L, Blanco-Quirós A, Garrote JA, Arranz E. Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients. *Allergol Immunopathol (Madr)* 2012; **40**: 3-8 [PMID: 21420224 DOI: 10.1016/j.aller.2010.11.003]

- 54 **De Stefano D**, Maiuri MC, Simeon V, Grassia G, Soscia A, Cinelli MP, Carnuccio R. Lycopene, quercetin and tyrosol prevent macrophage activation induced by gliadin and IFN-gamma. *Eur J Pharmacol* 2007; **566**: 192-199 [PMID: 17477920 DOI: 10.1016/j.ejphar.2007.03.051]
- 55 **Vincentini O**, Quaranta MG, Viora M, Agostoni C, Silano M. Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA2. *Clin Nutr* 2011; **30**: 541-546 [PMID: 21421277 DOI: 10.1016/j.clnu.2011.02.007]

**P- Reviewer:** Jadallah KA, Ribaldone DG, Rostami-Nejad M

**S- Editor:** Ma YJ **L- Editor:** A **E- Editor:** Ma YJ

